Discovering, Diagnosing and Fighting Cancer
Department of Pathology Careers
The Department of Pathology at Memorial Sloan Kettering is one of the largest in the world, consisting of pathologists, molecular diagnosticians, and researchers with expertise in a range of solid tumor types as well as hematopathology.
On our team, you’ll use state-of-the-art technology and the most-advanced diagnostic techniques to analyze thousands of tissue samples each year. We generate more than 160,000 diagnostic reports annually.
We also collaborate with medical teams and specialists throughout MSK to customize treatments for patients based on his or her individual diagnosis and disease. Our team also provides consultations for healthcare professionals around the world.
At MSK, we offer clinical autopsy examinations free of charge to families of anyone who had been under the treatment of our doctors at any time during the course of their lives. We strive to determine the effectiveness of their treatment, whether there were any identifiable complications, and the ultimate cause of death.
We also perform research through a medical donation program, called the Last Wish Program. Our researchers analyze tumors that they otherwise would not have been able to access safely while the patient was alive. The information is used to understand cancer and it’s progression.
Learn more about the Last Wish Program.
Our cytopathologists focus on solid tumors. We are supported by a dedicated staff and state-of-the-art infrastructure, including laboratories for immunohistochemistry, flow cytometry, cytogenetics, and molecular pathology.
We also have an active fine needle aspiration clinic, where we employ ultrasound guidance to more accurately direct biopsies. Learn more about the Fine Needle Aspiration Biopsy Clinic.
Our cytopathologists also use leading-edge telepathology systems so we can rapidly assess biopsies performed at MSK’s regional sites.
Pathologists on this team specialize in characterizing tumors based on the genetic changes in their cells. This diagnosis forms the basis for targeted therapies, for which tumors are analyzed and matched with appropriate drugs based on the genetic alterations that are driving cancer growth.
Since 2014, our team has been using MSK-IMPACT – a targeted test for mutations – to analyze the tumor DNA of essentially all MSK patients with advanced cancer. MSK-IMPACT is based on next-generation sequencing. The test allows us to detect hundreds of mutations and other genetic changes in tumors.
We also perform dozens of other sophisticated molecular tests on tumor samples. Separate laboratories perform studies for chromosomal alterations using karyotyping and fluorescence in-situ hybridization (cytogenetics), as well as assessing for hereditary mutations in cancer predisposition genes (diagnostic molecular genetics).
Everyone diagnosed with a blood cancer at MSK has his or her samples analyzed by a member of our expert hematopathology team. The team analyzes cancers that originate in the hematolymphoid system, including the blood, bone marrow, lymph nodes, and other lymphoid tissues.
We review about 20,000 samples every year. For each one, we provide a comprehensive diagnostic report that integrates complex information from morphological assessment, immunohistochemistry and flow cytometric analysis, and cytogenetic and molecular genetic studies.
Our laboratories are internationally recognized for their innovation in clinical test development. In particular, we are well regarded for our development of assays to detect minimal residual disease and comprehensive proteomic and genomic analysis, for which we work with the Molecular Diagnostics team.
Surgical pathology is one of the major functions of the Pathology Department. We analyze samples from surgical procedures and biopsies from all MSK facilities.
If a disease is complicated, we perform additional testing to provide a more accurate diagnosis and provide prognostic or therapeutic information as well.
We also perform diagnoses using frozen sections if a quicker diagnosis is needed. We work closely with surgical teams, and provide findings that can guide a procedure immediately while surgeries are taking place.
Research in the Experimental Pathology Division is focused on decoding the complex changes that occur in cancer cells. Members of this team investigate the molecular basis for the morphologic features observed when tumor tissue is examined under the microscope.
MSK’s experimental pathologists have pioneered much of the DNA analysis technology that’s used to improve diagnoses and develop personalized treatments. Thanks to this work, we now have extraordinary opportunities to provide insights into what causes cancer to form or progress, and to suggest strategies for blocking it.
Another area where the team has excelled is in subtyping rare tumors — a feat that has always been challenging on the basis of histology alone.
Center for Innovation
At MSK, you’ll have access to the Warren Alpert Center for Digital and Computational Pathology. Established in 2017, the center facilitates novel research and development in digital pathology and algorithmic computational pathology for clinical cancer care and research. We have slides, data and information regarding cancer diagnosis, treatment and research spanning more than 40 years.
The center is also a hub for existing digital pathology efforts to establish a fully digital workflow for our department.